Ocular Therapeutix™ to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
Get Alerts OCUL Hot Sheet
Join SI Premium – FREE
BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Jonathan Talamo, M.D., Chief Medical Officer, will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on Wednesday, July 13, 2016 at 9:30 a.m. ET. The conference will be held at the Le Parker Meridien Hotel in New York, NY.
A live audio webcast of the presentation can be accessed through the Calendar of Events section of the Company's website at investors.ocutx.com. A replay of the webcast will be available on the Company's website for two weeks following the presentation.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidate, DEXTENZA™ (sustained release dexamethasone) Intracanalicular Depot, is in Phase 3 clinical development for post-surgical ocular inflammation and pain and allergic conjunctivitis, and in Phase 2 clinical development for dry eye disease. A New Drug Application (NDA) for the post-operative ocular pain indication has been filed with FDA and has a Prescription Drug User Fee Act (PDUFA) target action date of July 24, 2016. A third Phase 3 clinical trial is being conducted for post-surgical ocular inflammation and pain. For glaucoma and ocular hypertension, the Company has completed its End-of-Phase 2 review with the FDA, and the first of two planned OTX-TP (sustained release travoprost) Phase 3 clinical trials is expected to be initiated in the third quarter of 2016. Ocular Therapeutix is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160706005373/en/
Investors
Ocular Therapeutix, Inc.
Brad Smith
Chief
Financial Officer
[email protected]
or
Burns
McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
[email protected]
or
Media
Ocular
Therapeutix, Inc.
Scott Corning
Vice President of Sales and
Marketing
[email protected]
Source: Ocular Therapeutix, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ocular Therapeutix (OCUL) Appoints Pravin U. Dugel as CEO
- Legal-Bay Pre-Settlement Funding Company Continues Focus on FELA and Railroad Cases Nationwide
- iFabric Corp. Announces US EPA Registration of TWO New Cutting-Edge Antimicrobial Technologies
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Cantor Fitzgerald, PDUFASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!